15-12B - Union Acquisition Corp. II (0001766146) (Filer)

8-K - Union Acquisition Corp. II (0001766146) (Filer)

8-K - Union Acquisition Corp. II (0001766146) (Filer)

25-NSE - Union Acquisition Corp. II (0001766146) (Subject)

425 - Union Acquisition Corp. II (0001766146) (Subject)

8-K - Union Acquisition Corp. II (0001766146) (Filer)

425 - Union Acquisition Corp. II (0001766146) (Subject)

8-K - Union Acquisition Corp. II (0001766146) (Filer)

425 - Union Acquisition Corp. II (0001766146) (Filed by)

425 - Union Acquisition Corp. II (0001766146) (Filed by)

5 - Union Acquisition Corp. II (0001766146) (Issuer)

4 - Union Acquisition Corp. II (0001766146) (Issuer)

4 - Union Acquisition Corp. II (0001766146) (Issuer)

Third Quarter 2021 Net Revenues Increased 35% to $106.8 Million Year-Over-Year with Adjusted EBITDA Up 27% Year-Over-Year to $24.5 Million First Nine Months Net Revenues Increased 33% to $283.2 Million, with LTM Net Revenues at $401.4 Million and LTM Adjusted EBITDA up to $100.3 Million Strong Double Digit Revenue Growth in Four Out of Five Business Units Driven by Market Share Gains and New Product Launches Closed Business Combination with Union Acquisition Corp. II on September 29, 2021, and Listed on The Nasdaq Global Market Under "PROC" on September 30, 2021 As a Result of the Business Combination, Procaps Group Ended the Third Quarter 2021 with $100.2 Million in Unrestricted Cash a

Combined Company to Begin Trading on the Nasdaq Global Market® Under "PROC" and "PROCW" On September 30, 2021 Approximately $160 Million of Gross Proceeds Strategically Positions Procaps, a Leading Global Pharmaceutical Technology and Healthcare Company Based in Latin America, to Accelerate M&A Roll-Up Initiative and Expand New Product Categories in B2B & B2C Segments Strong First Half 2021 Financial Results Position Procaps to Achieve Prior Full Year 2021 Guidance of Approximately $400 Million in Net Revenues and $105 Million of Adjusted EBITDA Procaps Will be Led by Ruben Minski, Founder, Chairman of the Board and Chief Executive Officer of Procaps Group, and Current Executive Team Inc

Union Acquisition Corp. II ("LATN") Shareholders Approve the Proposed Business Combination with Procaps Group and the Parties Agree to Close by September 30, 2021 Following the Closing of the Business Combination the Combined Company is expected to Trade on the Nasdaq Global Market® Under "PROC" and "PROCW" Union Acquisition Corp. II (NASDAQ:LATN, LATNU, LATNW))) ("LATN"), a publicly-traded special purpose acquisition company, announced today that its shareholders voted to approve the previously announced business combination (the "Business Combination") with Procaps Group, a leading integrated international healthcare and pharmaceutical company, and all other proposals presented at LATN'

Strong Financial Performance Enables Procaps Group to Launch Private Placement of Senior Notes to Refinance Existing Debt with New Institutional Investors Utilizing a Lower Cost of Capital & Expanded Duration to Accelerate Growth Strategy Procaps Group (as defined below), a leading integrated international healthcare and pharmaceutical company, today announced that it has launched a private offering of an aggregate principal amount of U.S. $115 million of senior notes (the "Senior Notes") of Procaps, S.A. ("Procaps"), a subsidiary of Procaps Group, in a private placement transaction led by Prudential Private Capital, to entities including one or more investment funds or managed accounts of

Extraordinary General Meeting of Union Acquisition Corp. II ("LATN") Shareholders to Approve the Proposed Business Combination with Procaps Group Will be Held on September 22, 2021, at 9:00 a.m. ET. Shareholders, as of the Close of Business on the Record Date of August 19, 2021, Are Encouraged to Vote Their Shares. LATN's Board of Directors Recommends Shareholders Vote "FOR" All of the Proposals at the Extraordinary General Meeting. For More Information, LATN's Shareholders Are Encouraged to Carefully Read the Entire Definitive Proxy Statement Filed in Connection with the Proposed Business Combination. Procaps Group, a leading integrated international healthcare and pharmaceutical compa

Procaps Group, a leading integrated international healthcare and pharmaceutical company, announced that in conjunction with Procaps Group's recent virtual analyst day and second quarter 2021 earnings results, it has released two new videos showcasing its Manufacturing and Research & Development facilities across Latin America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210823005193/en/ The videos take viewers behind the scenes of its facilities for a look at production lines for their oral solutions and other over-the-counter (OTC) and prescription drugs, nutritional supplements and high-potency clinical solutions. Please cli

Senior Financial Executive (Previously CFO of CFR Pharmaceuticals) Brings 25 Years of Financial and Operational Experience to Lead Procaps Global Rollout and M&A Initiatives Procaps Group, a leading integrated international healthcare and pharmaceutical company, has appointed Patricio Vargas as global Chief Financial Officer. Mr. Vargas has 25 years of public company finance experience with proven capabilities in global financial management, business development and global capital markets. He joins Procaps after serving as Finance Vice President & Treasurer at Empresas CMPC S.A. (CMPC.CL), a pulp and paper company with more than $5 billion in revenue that produces and markets solid wood

Second Quarter 2021 Net Revenues Increased 35% to $97 Million Year-Over-Year with Adjusted EBITDA Up 28% Year-Over-Year Company Reaffirms Revenue and Adjusted EBITDA Growth Trajectory for Full Year 2021 Procaps Group, a leading integrated international healthcare and pharmaceutical company, today announced its financial results for the second quarter ended June 30, 2021. Key Second Quarter 2021 Financial Highlights Net revenues increased by $25.1 million or 35% to $97.0 million compared to $71.9 million in the second quarter of 2020, driven by strong demand across our CDMO, branded Rx and OTC businesses in both our existing products as well as from our continued rollout of new product

Second Quarter 2021 Net Revenues Expected to Increase Over 25% Year-Over-Year, Resulting in First Half of 2021 Increasing Over 30% Year-Over-Year Company to Report on Second Quarter 2021 Results and Provide Full Year 2021 Guidance on August 12, 2021 Analyst Day and Investor Day Planned for Thursday, August 19th, at 10:00 a.m. Eastern Time Procaps Group, a leading integrated international healthcare and pharmaceutical company, today provided preliminary estimates of its second quarter 2021 net revenues for the three months ended June 30, 2021. In conjunction with the preliminary estimates, the Company also provided a business update and key milestone announcements ahead of its proposed b

Company Reaffirms Full Year 2021 Net Revenue Guidance of $397 Million and Adjusted EBITDA Guidance of $105 Million Business Combination Remains on Track to Close in the Third Quarter of 2021 Procaps Group, a leading integrated international healthcare and pharmaceutical company, and Union Acquisition Corp. II (NASDAQ:LATN, LATNU, LATNW))) ("LATN"), a publicly-traded special purpose acquisition company, today announced the filing of a registration statement on Form F-4 (the "Registration Statement"), which contains a preliminary proxy statement/prospectus, with the U.S. Securities and Exchange Commission ("SEC") in connection with their recently announced proposed business combination. The

Third Quarter 2021 Net Revenues Increased 35% to $106.8 Million Year-Over-Year with Adjusted EBITDA Up 27% Year-Over-Year to $24.5 Million First Nine Months Net Revenues Increased 33% to $283.2 Million, with LTM Net Revenues at $401.4 Million and LTM Adjusted EBITDA up to $100.3 Million Strong Double Digit Revenue Growth in Four Out of Five Business Units Driven by Market Share Gains and New Product Launches Closed Business Combination with Union Acquisition Corp. II on September 29, 2021, and Listed on The Nasdaq Global Market Under "PROC" on September 30, 2021 As a Result of the Business Combination, Procaps Group Ended the Third Quarter 2021 with $100.2 Million in Unrestricted Cash a

SC 13G/A - Union Acquisition Corp. II (0001766146) (Subject)

SC 13G - Union Acquisition Corp. II (0001766146) (Subject)

SC 13G - Union Acquisition Corp. II (0001766146) (Subject)

SC 13G/A - Union Acquisition Corp. II (0001766146) (Subject)

SC 13G/A - Union Acquisition Corp. II (0001766146) (Subject)